Výsledky vyhledávání

Akademický článek

Phase II trial of pembrolizumab, ipilimumab, and aspirin in melanoma: clinical outcomes and translational predictors of response.

Autor: Quandt Z; Department of Medicine, University of California San Francisco, San Francisco, CA, 94143, USA.; Diabetes Center, University of California San Francisco, San Francisco, CA, 94143, USA., Jacob S; Department of Medicine, University of California San Francisco, San Francisco, CA, 94143, USA.; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, 94143, USA., Fadlullah MZH; Departments of Oncological Sciences and Biomedical Informatics, University of Utah, Salt Lake City, UT, 84112, USA., Wu C; Division of Epidemiology, University of Utah, Salt Lake City, UT, 84112, USA., Wu C; Department of Medicine, University of California San Francisco, San Francisco, CA, 94143, USA.; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, 94143, USA., Huppert L; Department of Medicine, University of California San Francisco, San Francisco, CA, 94143, USA.; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, 94143, USA., Levine LS; Department of Medicine, University of California San Francisco, San Francisco, CA, 94143, USA.; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, 94143, USA., Sison P; Department of Medicine, University of California San Francisco, San Francisco, CA, 94143, USA.; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, 94143, USA., Tsai KK; Department of Medicine, University of California San Francisco, San Francisco, CA, 94143, USA.; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, 94143, USA., Chow M; Department of Medicine, University of California San Francisco, San Francisco, CA, 94143, USA.; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, 94143, USA., Kang JH; Diabetes Center, University of California San Francisco, San Francisco, CA, 94143, USA., Hwang J; Department of Medicine, University of California San Francisco, San Francisco, CA, 94143, USA.; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, 94143, USA., Lee JC; Department of Medicine, University of California San Francisco, San Francisco, CA, 94143, USA.; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, 94143, USA., Oglesby A; Department of Medicine, University of California San Francisco, San Francisco, CA, 94143, USA.; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, 94143, USA., Venegas J; Huntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, UT, 84112, USA.; Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT, 84112, USA., Brintz BJ; Division of Epidemiology, University of Utah, Salt Lake City, UT, 84112, USA., Tan AC; Departments of Oncological Sciences and Biomedical Informatics, University of Utah, Salt Lake City, UT, 84112, USA.; Huntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, UT, 84112, USA., Anderson MS; Department of Medicine, University of California San Francisco, San Francisco, CA, 94143, USA.; Diabetes Center, University of California San Francisco, San Francisco, CA, 94143, USA., Rosenblum MD; Dermatology, University of California San Francisco, San Francisco, CA, 94143, USA., Young A; Diabetes Center, University of California San Francisco, San Francisco, CA, 94143, USA. Arabella.Young@hci.utah.edu.; Huntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, UT, 84112, USA. Arabella.Young@hci.utah.edu.; Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT, 84112, USA. Arabella.Young@hci.utah.edu., Daud AI; Department of Medicine, University of California San Francisco, San Francisco, CA, 94143, USA. Adil.Daud@ucsf.edu.; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, 94143, USA. Adil.Daud@ucsf.edu.

Publikováno v: BJC reports [BJC Rep] 2024 Jun 24; Vol. 2 (1), pp. 46. Date of Electronic Publication: 2024 Jun 24.

Zobrazit plný text záznamu

Report

Refractory Pure Red Blood Cell Aplasia Secondary to Major ABO-Incompatible Allogeneic Stem Cell Transplantation Successfully Treated With Daratumumab.

Autor: Wu C; Department of Medicine, University of Arizona, Tucson, AZ, USA., Manchen P; Department of Pathology, University of Arizona, Tucson, AZ, USA., Edelman A; Department of Pathology, University of Arizona, Tucson, AZ, USA., Husnain M; Department of Medicine, University of Arizona, Tucson, AZ, USA.; University of Arizona Cancer Center, Tucson, AZ, USA., Katsanis E; Department of Medicine, University of Arizona, Tucson, AZ, USA.; Department of Pathology, University of Arizona, Tucson, AZ, USA.; University of Arizona Cancer Center, Tucson, AZ, USA.; Department of Pediatrics, University of Arizona, Tucson, AZ, USA.; Department of Immunobiology, University of Arizona, Tucson, AZ, USA., Fuchs D; Department of Pathology, University of Arizona, Tucson, AZ, USA., Stephens L; Department of Pathology, University of California San Diego Health, La Jolla, CA, USA., Khurana S; Department of Medicine, University of Arizona, Tucson, AZ, USA.; University of Arizona Cancer Center, Tucson, AZ, USA.

Publikováno v: Journal of hematology [J Hematol] 2023 Dec; Vol. 12 (6), pp. 277-282. Date of Electronic Publication: 2023 Dec 09.

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání